| Name | Title | Contact Details |
|---|
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
At Strive Compounding Pharmacy, were pioneering a movement in personalized medicine. Ditching the one-size-fits-all approach, we specialize in customizing medications to fit the unique health conditions and wellness goals of each individual. Our commitment to whole-person health is evident in our comprehensive services ranging from hormone replacement and weight management to dermatology and veterinary care. As a rapidly growing company, we pride ourselves on our robust company culture, strong partnerships with healthcare providers, and the effectiveness, safety, and benefits of our compounded drugs. Our pursuit of uncompromised excellence in compounding, coupled with a proactive approach to healthcare, sets us apart in creating healthier and happier lives, while also educating the world on the crucial role that compound pharmacies play within a healthy society.
Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.